<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01608412</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001ABR19T</org_study_id>
    <nct_id>NCT01608412</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus</brief_title>
  <official_title>An Open-label Randomized Controlled Clinical Trial to Assess the Efficacy and Safety of the Conversion to Everolimus 3 Months After Kidney Transplantation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hospital de Clinicas de Porto Alegre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hospital de Clinicas de Porto Alegre</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study hypotheses to be tested in this study are:

        -  Conversion to everolimus at 3 months post-transplantation is safe and effective;

        -  Accurate noninvasive molecular diagnostic tests can replace biopsy at 3 months
           pre-conversion (for the diagnosis of subclinical cellular and/or humoral rejection,
           tissue fibrosis and calcineurin inhibitor-induced nephrotoxicity) in kidney transplant
           recipients;

        -  Follow-up biopsy at 12 months post-conversion (for the diagnosis of tissue fibrosis) can
           be replaced with accurate noninvasive molecular diagnostic tests in kidney transplant
           recipients.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>February 2012</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate cumulative patient and graft survival at 12 months post conversion</measure>
    <time_frame>one year</time_frame>
    <description>Patient and graft survival will be evaluated one year after randomization by Kaplan-Meier analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of estimated glomerular filtration rate 12 months post-conversion</measure>
    <time_frame>one year</time_frame>
    <description>- To assess the efficacy of conversion from tacrolimus to everolimus 12 months post-conversion by measuring the estimated glomerular filtration rate using the Modification of Diet in Renal Disease (MDRD) equation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Kidney Transplant Recipients</condition>
  <arm_group>
    <arm_group_label>Tacrolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.
Intervention arm: Tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The subjects included in the study will be clinically followed up for at least 12 months. The patients will be selected at 3 months post-transplant according to inclusion and exclusion criteria and randomized in a 1:1 ratio for conversion to everolimus or maintenance of tacrolimus therapy.
Intervention arm: Everolimus</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tacrolimus</intervention_name>
    <description>TACROLIMUS (C0 = 5-10 ng/mL) + MPS 1440 mg + Pred</description>
    <arm_group_label>Tacrolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Everolimus</intervention_name>
    <description>Everolimus (C0 = 6-10 ng/mL) + MPS 1440 mg + Pred</description>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients undergoing their first living- or deceased-donor kidney transplant who
             maintain a functioning graft 3 months post-transplant;

          -  Older than 18 years;

          -  Panel-reactive antibodies lower than 20%;

          -  Baseline immunosuppression with tacrolimus, mycophenolate sodium (MPS) and prednisone
             at randomization at 3 months.

        Exclusion Criteria:

          -  eGFR &lt; 35 mL/min at randomization;

          -  Urine protein-to-creatinine ratio &gt; 0.8 at randomization;

          -  Episode of acute rejection with Banff histological classification &gt; 1A in the first 3
             months post-transplant;

          -  Cholesterol &gt; 350 mg/dL or triglycerides &gt; 400 mg/dL with therapy at randomization;

          -  Active infection at randomization;

          -  Chronic liver disease;

          -  Refusal to participate in the study;

          -  Contraindications to kidney biopsy;

          -  Biopsy findings at 3 months post-transplant including borderline rejection, cellular
             rejection or antibody-mediated rejection.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luiz Felipe S. Gonçalves, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>HCPA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Luiz Felipe S. Gonçalves, MD</last_name>
    <email>lfgoncalves@hcpa.ufrgs.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Nisséia Jahn, RN</last_name>
    <email>nisseia@yahoo.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital de Clínicas de Porto Alegre</name>
      <address>
        <city>Porto Alegre</city>
        <state>RS</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>August 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 8, 2012</study_first_submitted>
  <study_first_submitted_qc>May 30, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <last_update_submitted>May 30, 2012</last_update_submitted>
  <last_update_submitted_qc>May 30, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 31, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>renal transplantation</keyword>
  <keyword>everolimus</keyword>
  <keyword>tacrolimus</keyword>
  <keyword>molecular evaluation</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

